XenoPort to sell 2.5 million shares Print E-mail
By Staff and Wire Reports   
Tuesday, 07 July 2009 15:43

Biopharmaceutical company XenoPort Inc. on Tuesday said it will sell 2.5 million shares of its common stock, increasing the number of outstanding shares by more than 9 percent. The proceeds will go to fund research and development of its drug candidates, possible sales and marketing activities and for general corporate purposes, the company said in a regulatory filing.

XenoPort also intends to grant the underwriters a 30-day option to purchase up to 375,000 additional shares to cover over-allotments, if any.

Morgan Stanley and Goldman Sachs are acting as joint book-runners for the offering.

XenoPort shares closed the regular trading session down 69 cents, or 3.1 percent, at $21.50, then lost another $2, or 9.30, to $19.50 in aftermarket electronic trading, after the offering was announced.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus